Friday and still NO 10Q. Probably monday ?

No problem!

What are you on about? I don't PUMP but is merely doing DD like your are. I never posted anywhere the sharecount

PeopleString Registration Statement Goes Effective

http://finance.yahoo.com/news/PeopleString-Registration-iw-3344547250.html?x=0&.v=1

Registration effective on 9/17. So filings with FINRA for CUSPID and ticker symbol should come anyday now?

FDA working to prevent radiation overdoses during CT scans
The U.S. Food and Drug Administration has been investigating reports that patients undergoing computed tomography (CT) brain perfusion scans were accidently exposed to excess radiation. The FDA found that when properly used, the CT scanners did not malfunction. Instead, it is likely that the improper use of the scanners resulted in these overdoses. However, the FDA has identified a series or promising steps to enhance the safety of these procedures. These steps could reduce the likelihood of radiation overexposure in the event of improper use of the CT scanners.

The FDA has sent a letter to the Medical Imaging and Technology Alliance (link below), the major professional industry organization for manufacturers of CT scanners and other radiological imaging devices, reporting on the results of the investigation and discussing possible CT equipment enhancements that could improve patient safety. The agency will hold follow up discussions with manufacturers on the changes.

Those changes include:
A console notification to alert the operator of a high radiation dose;
Providing particular information and training on brain-perfusion protocols to all facilities that receiving base CT equipment, whether or not the facilities purchase the related software enabling quantitative analysis of cerebral hemodynamics;
Clarification of parameters affecting dose, along with clear instructions on how to appropriately set those parameters; and
Organization of all dose-related information into one section of each user manual, in a dedicated dose manual, or indexed comprehensively in a concordance covering all manuals.

CT brain perfusion scans produce cross-sectional images of the head that evaluate blood flow in the brain. In an update released today, the FDA discussed findings of a probe into radiation overdoses in patients who received CT brain perfusion scans in hospitals located in California and Alabama.

Begun in 2009, the FDA’s investigation included information from the states and facilities where radiation overdoses occurred from 2008 to Oct. 26, 2010. The agency also inspected CT scanner equipment manufacturers.

The probe indicated that CT scanners, when properly used, did not result in overdoses. However, the investigation uncovered potential enhancements to CT equipment that could reduce the likelihood of radiation overexposure if improper use occurs – a goal of the agency’s Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging.

“Improving patient safety is part of our public health mission,” said Jeffrey Shuren, M.D., director of FDA’s Center for Devices and Radiological Health. “Patients should not have to worry that a device designed to diagnose an illness exposes them to unnecessary risks.”

Since the investigation began, the FDA is aware of at least 385 patients who received excessive radiation from CT brain perfusion scans, many undergoing the test to confirm the presence of a stroke, performed at five hospitals in California and one in Alabama.
While unnecessary radiation exposure should be avoided, a medically-needed CT scan has benefits that outweigh the radiation risks. Patients should follow their doctor’s recommendations for receiving CT scans.

ALL in FAVOR for AUTOMATED compounding and DISPENSING SYSTEMs SUCH AS the PHARM ASSIST/CARDIO ASSIST that has little competition. The future of RadioPharmaceuticals is Automated compounding and dispensing systems coupled with manufacturing of improved targeted imaging BIOMarkers that has lower radiation levels and next generation 3d/4D PET scanners. POSC is heavily involved in R&D partnerships to bring to market the last 2 components as well. The next 12-18months is going to be even bigger for POSC than most realize. We are talking about personal therapeutic treatment plans and diagnosis using 4D PET imaging.

NCEN>>On the move already>Great 8K out A/H yesterday>

NCEN>>>Watch this move this AM>>Big Gapper

NCEN Gapper this morning>Multi day run. Great 8K out A/H yesterday

Gapper this morning>>>Great

Yu are welcome. Beautiful share structure so this is going to run again today. Lots of positives in this company

That would be great! I'm getting fresh powder tomorrow and looking to buy more! Picked up 10,000K @ 0.05 today.

Thanks Sheep

Not many pinkys worth holding but this is definitely ONE OF THEM I AM GOING TO HOLD FOR THE $5+>>>Solid company, fully reporting, financing lined up for current and future projects, partnering with big companies. Lots of up and up here....

Short term target>>>0.45pps>>Mid Term $1.25 (2-3months) and Long Term $2-5+ pps. This is my conservative opinion>>>

NCEN ALERT>>>up 138% today on great news>>>8K out A/H with more breaking news:

On November 2, 2010, NACEL Energy (“the Company”) deposited $25,000 with Arizona Public Service Company (“APS), the funds being the good faith estimate provided by APS of the expected costs likely to be incurred to complete a System Impact Study (SIS) for the Snowflake wind project located in Navajo County, AZ.


NACEL Energy anticipates a period of several months, or longer, before the SIS can be completed by APS personnel. Should the results of the SIS be favorable and indicate the necessary electrical system and equipment upgrades to construct Snowflake are economically feasible, as currently anticipated by the Company, a then further period of time may occur before a final interconnection agreement can be executed with APS. .....

Great to see DGRI there...

NCEN Alert>>>8K out A/H with more great news>>>

NCEN>>>8K just out and more breaking news>>Multi day runner

Sheep>>>Can you sticky todays news and the 8k just out>>There is some important info in the 8k also...See below

On November 2, 2010, NACEL Energy (“the Company”) deposited $25,000 with Arizona Public Service Company (“APS), the funds being the good faith estimate provided by APS of the expected costs likely to be incurred to complete a System Impact Study (SIS) for the Snowflake wind project located in Navajo County, AZ.


NACEL Energy anticipates a period of several months, or longer, before the SIS can be completed by APS personnel. Should the results of the SIS be favorable and indicate the necessary electrical system and equipment upgrades to construct Snowflake are economically feasible, as currently anticipated by the Company, a then further period of time may occur before a final interconnection agreement can be executed with APS.


In the interim, important additional development milestones are underway concerning Snowflake including, without limitation, evaluating potential turbine partners and financing arrangements. Accordingly, the Company cautions that commissioning (operations) at Snowflake is not expected until the fourth quarter of fiscal 2010-11, or later depending on future events.


A copy of the press release pertaining to the foregoing is attached hereto as an exhibit

NCEN ALERT>>>Up 100% today on great news out this AM.Easy 5x bagger from this level

NCEN>>>UP 100% today of GREAT news out this AM>>>L2 is thin>>>Watch this one go....

NCEN>>Big NEws out this AM>>>Up 100% so far with super thin L2>>>Easy Multibagger from this level

Something tells me that the new directors of FGBF is 100% sure that something sifnificant is going to meterialize for this company between now and February 5th 2011 that is going to push the PPS way past $6 a share and six is actually going to be a cheap price....

been holding for a year. About time for this to run

Do what i can to contribute to the facts and keeping things straight....

MM's should anty up the PPS if they want more shares..Nobody selling down here but fools...

Watch the L2 closely...Several blocks of 100, 200 and 300 shares have gone through repeatedly today. I think the MM's are signalling each other that they need shares...another buy of 100 shares @ 0.74 went through..Lets see where this go! The float may all be lock up! This could make for a interesting afternoon and Monday if nobody sells anything significant...

Key resistance points 0.68, 0.80 and 0.86 then breakout...

Facebook Profile of World Corporate Assets Inc.

http://www.facebook.com/pages/Henderson-NV/World-Corporate-Assets-Inc/142867822392220

World Finance Capital Holdings Inc. is a subsidiary of World Corporate Assets Inc

The directors of World Finance Capital Holdings Inc. is:

Anthony Saviano (CEO and President)

Linkedin Profile:

http://www.linkedin.com/pub/anthony-saviano/9/aa9/356

Jesse Eichman
Oliver Gifford and John Hartnett.

Everything you all need to know about Mr John A Zehner:

John Zehner, President and CEO of NukeMed, Inc.

John Zehner has over 20 years of experience in the Nuclear Medicine field. Mr. Zehner has been part of several start-ups and mergers/acquisitions in his field.

•In 1993, he was a cofounder of Northern Virginia Isotopes, Inc. which was an independent nuclear pharmacy in the Washington D.C. market.
•In 1995, Mr. Zehner led the effort to form Eastern Isotopes, Inc. from three nuclear pharmacies in the Washington D.C. metro market.
•In 1998, Mr. Zehner founded a cyclotron based positron emission tomography production facility to produce FDG inside Eastern Isotopes, Inc. This company ultimately grew into one of the world’s largest producers of Positron emitting radioisotopes known as IBA molecular.
•In 2003, Mr. Zehner lead the effort to sell Eastern Isotopes, Inc. to IBA, S.A. a life science company located in Belgium.
•In 2004, Mr. Zehner founded NukeMed, Inc. and its subsidiary, DoseShield, Inc. that was focused on the automation of radiopharmaceutical compounding.
•In 2008, Mr. Zehner sold DoseShield to Positron Corporation as an earn-out sale.
•In 2009, Mr. Zehner consolidated the operations of Positron Corporation into Indiana to form a pharmaceutical manufacturing arm of the company.
•In 2010, Mr. Zehner opened a cGMP facility to complete the earn-out sale of DoseShield to Positron.
As COO of Positron, Mr. Zehner consolidated existing operations from Texas and Canada to Indiana. Mr. Zehner formed a sales organization and transferred the automation technology to Positron from DoseShield. Mr. Zehner established a cGMP facility and management team for the manufacture of FDA approved pharmaceuticals. During Mr. Zehner’s tenure, Positron was awarded a 510K FDA recognition for a Positron Emission Tomography imaging device, began sales of the device and established a joint venture to develop radiopharmaceutical automation with Covidien, one of the world’s largest radiopharmaceutical manufacturers.

As President and COO of Eastern Isotopes, Inc., Mr. Zehner grew the company from a regional distribution pharmacy serving the Washington DC metro area to a national pharmaceutical manufacturing, imaging and distribution company serving over 26 states. Under Mr. Zehner, company sales grew from around 4 million in 1998 to over 34 million in 2003. The company grew from 3 nuclear pharmacies and 50 employees to 14 facilities consisting of pharmaceutical manufacturing plants, nuclear medicine imaging clinics and nuclear pharmacies with approximately 300 employees.

Mr. Zehner was project leader for selling Eastern Isotopes, Inc. to IBA, SA, a Belgium life science company, in 2001 with an earn-out period. The enterprise value of the sale was approximately $50 million. During the earn-out period, Mr. Zehner had advisory responsibilities for IBA S. A. affiliates in France, Italy and Belgium.

Mr. Zehner regularly presented overviews of Eastern Isotopes, Inc. and Positron to academic institutions, investors, large clients and other nuclear medicine vendors. He delivered an educational presentation to the Institute of Clinical PET (currently the Academy of Molecular Imaging) about opportunities in cyclotrons. He presented on behalf of Eastern Isotopes, Inc., who was ultimately awarded the largest contract for FDG at the time with a group purchasing organization (GPO), the GPO represented over 1500 hospitals. Eastern Isotopes, Inc. developed joint ventures with the University of West Virginia, the Medical College of Virginia and Philips (Formally ADAC) during Mr. Zehner’s tenure.

Mr. Zehner has experience that includes extensive regulatory affairs with the Nuclear Regulatory Commission (NRC), the Food and Drug Administration (FDA), the Department of Transportation (DOT) and various state pharmacy boards. He has developed and presented budgets, financial projections and market outlooks to investors and various financial institutions on numerous occasions. He has hands on experience as a nuclear pharmacist in 5 different states and as a radiation safety officer for 4 different companies, including Positron, Eastern Isotopes, Inc. and GE Healthcare (Formally Amersham). He also has direct experience as a cyclotron operator for drug manufacturing.

Mr. Zehner lives in Indianapolis, Indiana and is a guest speaker at Purdue University College of Pharmacy and a member of the American Pharmaceutical Association, the American Nuclear Society and the Society of Nuclear Medicine. Mr. Zehner is married to wife Lori with three daughters, Kayla, Paige and Maci. Mr. Zehner holds pharmacy licenses in 3 states and is recognized by the Nuclear Regulatory Commission as an authorized user and Radiation Safety officer. Mr. Zehner has a patent involving the automation of nuclear medicine products

It appears (according to the new NukeMed website) that Mr Zehner is still the CEO and President of NukeMed Inc. (Positron also have shares in NukeMed Inc.).

NukeMed, Inc. focuses on the manufacture, distribution and imaging of radiopharmaceutical products. NukeMed, Inc. will provide turnkey imaging and production facilities for Nuclear medicine, as well as, assistance with the handling and automation of radioisotopes, operation of cyclotron facilities and general distribution of radioactive material. NukeMed, Inc. offers assistance with various regulatory issues related to radioactive material, including but not limited to: the practice of pharmacy, USP-797, the Food and Drug Administration (FDA), the Department of Transportation (DOT) and the Nuclear Regulatory Commission (NRC

NukeMed Inc. http://www.nukemed.com/index.html

It appears to me if I put it all together based on todays PR and reading between the lines (you have to do that sometimes with Pat)that our Mr Zehner is still very much involved with Positron going forward and he is moving from the R&D side to actually manufacturing and bringing it to market. Very smart move since he has some pretty strong connections at Purdue University. Perdue have one of the largest Nuclear Pharmacy campuses

http://web.ics.purdue.edu/~nuclear/

NBRI receives BIG News today>>>Up 18% so far on 7.5Mill sponsorship from USCIS

NBRI>>>BIG NEws out today>>>Receives 7.5Mill sponsorship from the USCIS for the Ruby Gold Project

NBRI>>BIG NEWS TODAY>>>Receives $7.5Mil sponsorship from USCIS regional center for the Ruby Gold Project in Sierra County, California, through EB5 Program

I love this the more I think about the positive reasons for wanting to do the R/S. My original solid DD still holding up here...

Thanks for clarifying that. But why reduce the number of shares to such a tight SS? Won't that create liquidity issues? through this we can assume that IMD is cash rich? Also by trading above $1 per share it then appears that their plan is to uplist asap? This good be really good.

Just trying to look at the positive reasoning behing the new companies strategies

Also as per the IHUB:

•Outstanding Shares
221,134,316 as of May 31, 2008
•Authorized Shares
700,000,000 as of May 31, 2008
•Float (shares)
51,134,316 as of May 31, 2008

in the filing it says 700000 AS shares? Which is correct now and what is the correct OS and Float as of today or yesterday? Anybody know or have an idea how to confirm?

The statement in the filing says 1 share = 5000 of common shares after the R/S. That just doesn't make sense to me. I hold 500000 of common stock right now after the R/S I would own 25Mill shares? How can they increase the common stock by 5000 for every share but the AS remains 700000 shares?

A few reasons:

1. To raise market awareness for the company and products/services in a larger market (national or international)and with larger organizations
2. To raise capital for growth through acquisitions or expansions
3. Cheaper to buy a clean shell already on the OTCBB or pinksheets for $100,000-300,000USD than to try and do a IPO which can cause several million USD.

Most of the small biotechs/pharma's/healthcare/medical devices companies that has a real product/services, need investment dollars to grow and need to establish business partnerships with the big companies in the industry, decide to go this way.

Typically within a couple years of going public and successfully delivering on business milestones such as sales, revenue, new products/services, the company becomes a prime takeover target by a larger competitor that wants the IP. Having a unique IP is huge coupled with a very strong core of directors to execute.

iMD has both....

1. iMD already has an established recurring revenue from a large physician/customer base in NJ, NY, FL, CA, TX, VA, etc. and their customer base will just get bigger over the next few years because of the new Federal Health Care programs the NIH is rolling out that provides better support by delivering more billing codes and rates for healthcare services with a proven track record for reducing future medical expenses through proactive healthcare treatment and diagnostics programs such as the iMD HeartScan program (to name but one of their services)
2. iMD has a rock solid management team ....See message http://investorshub.advfn.com/boards/read_msg.aspx?message_id=54814327

If they roll all of the iMD companies (5+) into ICBU as the umbrella company then we can easily see the PPS at several $$$ if not more depending on valuation (share structure and financials 2009/2010. Worse case scenario if just 2 or 3 of iMD companies get rolled into ICBU then we can still see a PPS of somewhere in the .20-30 range.